---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-113764"
form_type: "8-K"
ticker: "LXEO"
cik: "0001907108"
company_name: "Lexeo Therapeutics, Inc."
filed_at: "2024-10-09T23:59:59+00:00"
generated_at: "2026-05-30T17:30:23.576264+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lexeo updates LX2020 cohort data timeline to late Q1/early Q2 2025; LX1001 data at CTAD Oct 2024

## Summary
- Expects to share Cohort 1 data from LX2020 for PKP2-ACM in late Q1 or early Q2 2025.
- Plans to present LX1001 data for APOE4-associated Alzheimer's at CTAD conference in Oct 2024.
- Corporate presentation posted on website; used for investor meetings going forward.
- No changes to financial guidance or capital structure disclosed in the filing.

## SEC filing metadata
- accession: 0000950170-24-113764
- form_type: 8-K
- ticker: LXEO
- cik: 0001907108
- company_name: Lexeo Therapeutics, Inc.
- filed_at: 2024-10-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1907108/000095017024113764/0000950170-24-113764-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1907108/000095017024113764/lxeo-20241009.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-113764
- JSON: https://secwatch.observer/filing/0000950170-24-113764.json
- Plain text: https://secwatch.observer/filing/0000950170-24-113764.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.